| 10.53 0.35 (3.44%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.06 | 1-year : | 21.93 |
| Resists | First : | 14.61 | Second : | 18.78 |
| Pivot price | 11.39  |
|||
| Supports | First : | 7.86 | Second : | 6.54 |
| MAs | MA(5) : | 9.5  |
MA(20) : | 12.95 |
| MA(100) : | 21.97 |
MA(250) : | 20.17 |
|
| MACD | MACD : | -2.5 |
Signal : | -2.6 |
| %K %D | K(14,3) : | 22.1 |
D(3) : | 15.9 |
| RSI | RSI(14): 35.8 |
|||
| 52-week | High : | 30.98 | Low : | 7.86 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BCAX ] has closed above bottom band by 44.0%. Bollinger Bands are 137.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.42 - 11.46 | 11.46 - 11.5 |
| Low: | 10.01 - 10.05 | 10.05 - 10.1 |
| Close: | 10.45 - 10.52 | 10.52 - 10.58 |
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Tue, 10 Nov 2026
Bicara Therapeutics Inc (BCAX) Q3 2026 Earnings Call Highlights: Strong Enrollment Momentum and ... - Yahoo Finance
Mon, 09 Nov 2026
Bicara Therapeutics Inc. Common Stock Q3 2026 Earnings Call Summary - Yahoo Finance
Mon, 09 Nov 2026
BCAX: Bicara Therapeutics Inc. filed SEC Form 8-K: Results of... - Quantisnow
Wed, 28 Oct 2026
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
Thu, 03 Sep 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Tue, 11 Aug 2026
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 10 (%) |
| Held by Institutions | 103.2 (%) |
| Shares Short | 10,300 (K) |
| Shares Short P.Month | 11,190 (K) |
| EPS | -3.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.2 % |
| Return on Equity (ttm) | -41.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -135 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -3.42 |
| PEG Ratio | 0 |
| Price to Book value | 1.48 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|